137 related articles for article (PubMed ID: 33923621)
21. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
23. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?
Akkas BE; Demirel BB; Dizman A; Vural GU
Ann Nucl Med; 2013 Oct; 27(8):756-63. PubMed ID: 23793926
[TBL] [Abstract][Full Text] [Related]
24. Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative
Lim WS; Oh JS; Roh JL; Kim JS; Kim SJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2018 Feb; 77():98-104. PubMed ID: 29362133
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
[TBL] [Abstract][Full Text] [Related]
26. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
27. Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer: A Systematic Review.
Creff G; Devillers A; Depeursinge A; Palard-Novello X; Acosta O; Jegoux F; Castelli J
JAMA Otolaryngol Head Neck Surg; 2020 May; 146(5):471-479. PubMed ID: 32215611
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of
Mohamed E; Needham A; Psarelli E; Carroll M; Vinjamuri S; Sanghera B; Wong WL; Halloran C; Ghaneh P
Eur J Surg Oncol; 2020 Aug; 46(8):1532-1538. PubMed ID: 32070641
[TBL] [Abstract][Full Text] [Related]
29. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
[No Abstract] [Full Text] [Related]
30. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
31. Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model.
Spanier G; Weidt D; Hellwig D; Meier JKH; Reichert TE; Grosse J
Oncotarget; 2021 Jan; 12(1):37-48. PubMed ID: 33456712
[TBL] [Abstract][Full Text] [Related]
32. Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: A multiparametric PET-CT study.
Li K; Sun H; Guo Q
Eur J Radiol; 2019 Apr; 113():153-157. PubMed ID: 30927941
[TBL] [Abstract][Full Text] [Related]
33. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma.
Li Y; Hofheinz F; Furth C; Lili C; Hua W; Ghadjar P; Zschaeck S
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1752-1761. PubMed ID: 29679113
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer.
Tamandl D; Ta J; Schmid R; Preusser M; Paireder M; Schoppmann SF; Haug A; Ba-Ssalamah A
Eur J Radiol; 2016 Mar; 85(3):540-5. PubMed ID: 26860665
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
Yilmaz B; Dağ S; Ergul N; Çermik TF
Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
[TBL] [Abstract][Full Text] [Related]
37. The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma.
Lee Y; Yoo IR; Boo SH; Kim H; Park HL; Hyun O J
Nucl Med Mol Imaging; 2017 Mar; 51(1):69-78. PubMed ID: 28250860
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment
Ha LN; Chau ND; Bieu BQ; Son MH
Nucl Med Mol Imaging; 2022 Aug; 56(4):181-187. PubMed ID: 35846416
[TBL] [Abstract][Full Text] [Related]
39. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.
Maharjan S; Sharma P; Patel CD; Sharma DN; Dhull VS; Jain SK; Thulkar S; Malhotra A; Kumar R
Nucl Med Commun; 2013 Aug; 34(8):741-8. PubMed ID: 23676840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
